Chen-Yu Huang
Biographic Data
| ID | 7902049 |
|---|---|
| NAME | Chen-Yu Huang |
| GIVEN NAMES | Chen-Yu |
| FAMILY NAME | Huang |
| SIGNATURE | HUANG C |
| AFFILIATIONS | National Yang Ming Chiao Tung University |
| ORCID | 0000-0003-3527-2789 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2020 |
| H-INDEX | 0 |
Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with Figo IIIC Serous-Type Tubo-Ovarian Cancer
The use of weekly chemotherapy for the treatment of patients with advanced-stage serous-type epithelial Tubo-ovarian cancer (ETOC), and primary peritoneal serous carcinoma (PPSC) is acceptable as the front-line postoperative chemotherapy after primary cytoreductive surgery (PCS). The main component of dose-dense chemotherapy is weekly paclitaxel (80 mg/m 2 ), but it would be interesting to know what is the difference between combination of triwee…
No prominent works on this page.
Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with Figo IIIC Serous-Type Tubo-Ovarian Cancer
The use of weekly chemotherapy for the treatment of patients with advanced-stage serous-type epithelial Tubo-ovarian cancer (ETOC), and primary peritoneal serous carcinoma (PPSC) is acceptable as the front-line postoperative chemotherapy after primary cytoreductive surgery (PCS). The main component of dose-dense chemotherapy is weekly paclitaxel (80 mg/m 2 ), but it would be interesting to know what is the difference between combination of triwee…
Cancer (1 work) · Carboplatin (1 work) · Chemotherapy (1 work) · Cisplatin (1 work) · Endometrial and Cervical Cancer Treatments (1 work) · Internal Medicine (1 work) · Intraperitoneal and Appendiceal Malignancies (1 work) · Medicine (1 work) · Oncology (1 work) · Ovarian cancer (1 work)